TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7745464
Drug: Mechanical devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical devices (e.g., graduated leg stockings; external pneumatic calf compression)
Study: 7745464
Drug: Pharmacological agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological agents (e.g., low dose heparin)
Study: 2643933
Drug: Imipramine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 0.5 mg/kg/d
Study: 2643933
Drug: Imipramine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 1.5 mg/kg/d
Study: 2643933
Drug: Imipramine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 3 mg/kg/d
Study: 1092731
Drug: Naproxen 400
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 400 mg daily
Study: 19107337
Drug: Duodenal acidification
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal acidification (0.1 N HCl, 20 ml/min for 5 min)
Study: 19107337
Drug: Pure water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure water infusion (20 ml/min for 5 min)
Study: 10999643
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment with a focus on maintaining diastolic blood pressure (DBP) above mid- to low 80s.
Study: 1937790
Drug: Salmonella typhi
Normalized name: Salmonella Typhi Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmonella typhi Ty21a vaccine (10^9 CFU per dose, three doses)
Study: 6341435
Drug: Intranasal insufflation
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal insufflation of 50 mg of dry ragweed or timothy grass pollen (antigen challenge)
Study: 22607553
Drug: Senior centre
Normalized name: docosahexaenoic acid / phosphatidylserine Oral Capsule [Senior Moment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senior centre group programme (weekly meetings)
Study: 17054896
Drug: 350‐mm(2) Baerveldt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350‐mm(2) Baerveldt glaucoma implant
Study: 11932320
Drug: Pegvisomant 20
Normalized name: pegvisomant 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant 20 mg/d for 7 d
Study: 11932320
Drug: Octreotide 50
Normalized name: octreotide 50 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 50 microg thrice daily for 7 d
Study: 1724116
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg daily for 2 weeks)
Study: 22691058
Drug: Adjunctive application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive application of locally delivered minocycline ointment in association with flap surgery (FM)
Study: 16437375
Drug: Glutamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (30 g/d) for 7 days
Study: 15215812
Drug: GIK therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK therapy (in diabetic patients)
Study: 10902791
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy before estrogen treatment
Study: 8888720
Drug: nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 300 mg at night
Study: 8888720
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg in the morning
Study: 8888720
Drug: nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 300 mg at night and omeprazole 20 mg in the morning
Study: 3906942
Drug: Indoprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoprofen (400 mg)
Study: 3305488
Drug: Propranolol (80,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80, 160, or 320 mg/day)
Study: 3305488
Drug: Chlordiazepoxide (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (30, 45, or 75 mg/day)
Study: 28762135
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg twice daily
Study: 27582675
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (1 intravitreal bevacizumab injection 1.25 mg + PDT)
Study: 22544804
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF 300 mg once daily for 72 weeks
Study: 22544804
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 72 weeks
Study: 10707917
Drug: Prescription NSAIDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription NSAIDs
Study: 10707917
Drug: Ibuprofen (dosages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (dosages < or =1,200 mg/day)
Study: 10707917
Drug: Ibuprofen (dosages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (dosages >1,200-<2,400 mg/day)
Study: 10707917
Drug: Ibuprofen (dosages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (dosages > or =2,400 mg/day)
Study: 9195347
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg i.v. lidocaine 90 seconds prior to endotracheal intubation
Study: 1287615
Drug: Cefaclor AF
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor AF (750 mg)
Study: 1287615
Drug: Cefaclor AF
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor AF (500 mg) alone
Study: 1287615
Drug: Cefaclor immediate
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor immediate release (500 mg) alone
Study: 23883636
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (60-minute comprehensive exercise program, twice a week for 3 months)
Study: 23883636
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + amino acid supplementation (6 g/day for 3 months)
Study: 23883636
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplementation (6 g/day for 3 months)
Study: 21046171
Drug: Modafinil 100
Normalized name: modafinil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 100 mg once daily
Study: 18029066
Drug: Study vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study vaccine (Group 1)
Study: 18029066
Drug: Vero cells
Normalized name: Vero Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero cells vaccine (Group 2)
Study: 16271155
Drug: Local steroid
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroid treatment (fluticasone) for 4 weeks
Study: 12114411
Drug: S-1 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 administered once daily at a dose of 50 mg/m2/day for 21 consecutive days
Study: 12114411
Drug: S-1 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 administered once daily at a dose of 60 mg/m2/day for 21 consecutive days
Study: 12114411
Drug: Correlation analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation analysis of diarrhea grade with pharmacokinetics
Study: 11123415
Drug: Hydrogel barrier/repair
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel barrier/repair cream
Study: 11123415
Drug: Petrolatum-based cream
Normalized name: PETROLATUM BASE
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum-based cream
Study: 8737631
Drug: 1000 mg/d
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/d HR
Study: 8737631
Drug: 1000 mg/d
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/d and 500 mg/d HR
Study: 8737631
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d HCE
Study: 1327655
Drug: S-adenosyl-L-methionine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (oral administration)
Study: 31110092
Drug: Mifamurtide combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifamurtide combined with postoperative chemotherapy
Study: 27707990
Drug: Ceftolozane/tazobactam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/tazobactam (1.5 g IV every 8 h)
Study: 27707990
Drug: Levofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (750 mg once daily)
Study: 27707990
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g IV every 8 h)
Study: 24157825
Drug: Metformin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (in women without insulin resistance)
Study: 24157825
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in women without insulin resistance)
Study: 24157825
Drug: Metformin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (in women with insulin resistance)
Study: 24157825
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in women with insulin resistance)
Study: 16953132
Drug: Comprehensive lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive lifestyle modification program (16 weeks, weekly meetings, individually prescribed exercise and diet, stress management, self-monitoring)
Study: 10839470
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg 12‐hourly for 48 hours
Study: 10322847
Drug: Jiangtangkang (JTK),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangtangkang (JTK), 8 g each time, 3 times per day for 2 months
Study: 10322847
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Glibenclazide for newly discovered NIDDM, no treatment for poorly controlled NIDDM)
Study: 8489450
Drug: PhXA41 (0.006%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 (0.006%) twice daily during week 1 and pilocarpine (2%) three times daily during week 2
Study: 8489450
Drug: Pilocarpine (2%)
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine (2%) three times daily during week 1 and PhXA41 (0.006%) twice daily during week 2
Study: 3501692
Drug: Cimetidine and
Normalized name: Cimetidine and sodium alginate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine and antacid
Study: 31718504
Drug: Journal interventions
Normalized name: Journavx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Journal interventions (e.g., Basic Science Checklist by Stroke)
Study: 29394998
Drug: heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin + a glycoprotein IIb/IIIa inhibitor
Study: 27117698
Drug: CT-P13 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 (5 mg/kg) administered intravenously every 8 weeks from week 62 to week 102
Study: 25586332
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) with microskin autografting
Study: 24257391
Drug: Pudendal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudendal nerve block (PNB) with 0.3 mL/kg 0.25% bupivacaine and 1 µg/kg clonidine
Study: 24257391
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block (CB) with 1 mL/kg 0.25% bupivacaine and 1 µg/kg clonidine
Study: 11054030
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (imipramine plus oxybutynin)
Study: 9202790
Drug: High-density formula
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density formula (30 kcal/oz) at 145 ml/kg/day
Study: 9202790
Drug: Low-density formula
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-density formula (24 kcal/oz) at 180 ml/kg/day
Study: 7972390
Drug: Cocoa capsules
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa capsules (pharmacological equivalent)
Study: 2537349
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (10 capsules/day, 1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid)
Study: 2537349
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 capsules of 50% olive oil, 50% corn oil)
Study: 19392995
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for pollen allergens
Study: 11577374
Drug: Voriconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (200 mg, b.i.d.)
Study: 9850026
Drug: BEACOPP (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEACOPP (both standard and escalated dose)
Study: 28589965
Drug: Exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatment (2 sessions)
Study: 23764690
Drug: Gradual titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual titration of paroxetine (2.5 mg on alternate days up to 10 mg in 7 days)
Study: 23764690
Drug: Abrupt initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abrupt initiation of paroxetine (10 mg)
Study: 16821647
Drug: New didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: New didanosine formulation (100 mg tablets)
Study: 16821647
Drug: Conventional didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional didanosine formulation (100 mg tablets)
Study: 2064401
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin E solution (DL-alpha-tocopherol in dimethyl sulfoxide) applied to three nails for 6 months
Study: 2064401
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin E solution applied to all nails for an additional 6 months after initial treatment
Study: 19906801
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (120 mg/d)
Study: 19906801
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (80 mg/d)
Study: 17989574
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (ITD) injections (0.3 mL on days 1, 3, and 5) plus 48 mg methylprednisolone
Study: 17989574
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (ITD) injections
Study: 12444816
Drug: Bromazepam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (6 mg/day)
Study: 2288653
Drug: 3 megaunits
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 megaunits of rIFN a‐2b s.c. thrice weekly for 4 months
Study: 30215171
Drug: Nutritional sodium
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional sodium selenate (0.32 mg, 3 times daily)
Study: 30215171
Drug: Supranutritional sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supranutritional sodium selenate (10 mg, 3 times daily)
Study: 26455957
Drug: Vegetable soup
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable soup with added monosodium L-glutamate (0.5 g/100 ml)
Study: 24470436
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 6.5 mg/kg/day for 8 weeks
Study: 24043137
Drug: Famitinib (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famitinib (doses increased from 4 to 30 mg, administered once daily)
Study: 18838929
Drug: Isotonic fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic fluids (NaCl = 140 mEq/L)
Study: 18838929
Drug: Hypotonic fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic fluids (NaCl <100 mEq/L)
Study: 14528702
Drug: Complementary therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary therapies
Study: 8898646
Drug: Wheat amylase
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat amylase inhibitor preparation (3.0 mg/mL)
Study: 8898646
Drug: Wheat amylase
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat amylase inhibitor preparation (4.5 mg/mL)
Study: 8898646
Drug: Wheat amylase
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat amylase inhibitor preparation (6.0 mg/mL)
Study: 7049504
Drug: Sulindac 400
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac 400 mg once daily (at 9:00 P.M.)
Study: 7049504
Drug: Sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 200 mg b.i.d. (at 9:00 A.M. and 9:00 P.M.)
Study: 7049504
Drug: Sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 200 mg b.i.d.
Study: 7049504
Drug: Sulindac 400
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac 400 mg once daily
Study: 17997623
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (age-appropriate movie)
Study: 15889697
Drug: Enalaprilat (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (0.625 mg) IV infusion
Study: 12171952
Drug: Anti-H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H pylori treatment (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g, all twice daily for one week followed by placebo for four weeks)
Study: 12171952
Drug: Anti-H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H pylori treatment (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g, all twice daily for one week followed by omeprazole 20 mg once daily for four weeks)
Study: 12171952
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for five weeks
Study: 9570242
Drug: De Nol
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De Nol 120 mg q.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 2 weeks
Study: 9570242
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 2 weeks
Study: 9570242
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 1 week
Study: 7664546
Drug: CDP571 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 0.1 mg/kg
Study: 7664546
Drug: CDP571 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 0.3 mg/kg
Study: 7664546
Drug: CDP571 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 1.0 mg/kg
Study: 7664546
Drug: CDP571 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 3.0 mg/kg
Study: 831465
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of vaccine (VV)
Study: 831465
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of vaccine followed by placebo (VP)
Study: 831465
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of placebo (PP)
Study: 831465
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two doses of the vaccine
Study: 28678121
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in the U.S.
Study: 26218826
Drug: Cryolipolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryolipolysis treatment (60-minute cycle followed by a 2-minute massage, then a second 60-minute cycle with 50% treatment area overlap)
Study: 26218826
Drug: Cryolipolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryolipolysis treatment
Study: 23150149
Drug: NAT2 genotype-guided
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAT2 genotype-guided treatment (PGx-treatment: 7.5 mg/kg for rapid acetylators, 5 mg/kg for intermediate acetylators, 2.5 mg/kg for slow acetylators)
Study: 23150149
Drug: Conventional standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional standard treatment (STD-treatment: approx. 5 mg/kg of isoniazid for all)
Study: 16669547
Drug: Prima Difesa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prima Difesa (1 administration) in Group C
Study: 12897580
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% QD added to pre-existing therapy (group A)
Study: 11106218
Drug: 5-mg nicotine
Normalized name: nicotine 0.5 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg nicotine patch (placebo)
Study: 11106218
Drug: 15-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-mg nicotine patch plus nicotine inhaler
Study: 8975347
Drug: Mepivacain Hydrochloride
Normalized name: Mepivacaine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacain Hydrochloride with 20 mg of Triamcinolone Hexaacetonide
Study: 1582237
Drug: Midazolam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.2 mg/kg intravenously) with flumazenil (0.1 to 0.2 mg intravenously)
Study: 1582237
Drug: Fentanyl (0.002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.002 mg/kg intramuscularly)
Study: 31790343
Drug: Neuropsychological Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropsychological Assessment Battery, Screening Module (S-NAB) administered to the S-mTBI group with symptom and test coaching to simulate impairment.